ARCA biopharma (ABIO) USPTO patents

Utility

Methods and compositions involving bucindolol for the treatment of atrial fibrillation

17 Jan 23

The current methods and compositions relate to treatment of atrial fibrillation with bucindolol in patients, including patients with heart failure, after being determined to be homozygous Arg389 in the β1 adrenergic receptor gene.

Michael Bristow, Christopher Dufton

Filed: 8 Feb 21

Utility

Methods and compositions involving (S)-bucindolol

27 Sep 22

Disclosed is bucindolol substantially free of its R-stereoisomer.

Michael R. Bristow, Jonathan D. Port

Filed: 13 Dec 18

Utility

Methods and Compositions Involving Bucindolol for the Treatment of Atrial Fibrillation

19 Aug 21

The current methods and compositions relate to treatment of atrial fibrillation with bucindolol in patients, including patients with heart failure, after being determined to be homozygous Arg389 in the β1 adrenergic receptor gene.

Michael Bristow, Christopher Dufton

Filed: 8 Feb 21

Utility

Methods and compositions involving bucindolol for the treatment of atrial fibrillation

23 Feb 21

The current methods and compositions relate to treatment of atrial fibrillation with bucindolol in patients, including patients with heart failure, after being determined to be homozygous Arg389 in the β1 adrenergic receptor gene.

Michael Bristow, Christopher Dufton

Filed: 5 May 20

Utility

Methods and Compositions Involving Bucindolol for the Treatment of Atrial Fibrillation

26 Aug 20

The current methods and compositions relate to treatment of atrial fibrillation with bucindolol in patients, including patientswith heart failure, after being determined to be homozygous Arg389 in the β1 adrenergic receptor gene.

Micheal Bristow, Christopher Dufton

Filed: 4 May 20

Utility

Methods and Compositions Involving (S)-bucindolol

27 Nov 19

Disclosed is bucindolol substantially free of its R-stereoisomer.

Michael R. Bristow, Jonathan D. Port

Filed: 12 Dec 18